Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders

Alessandro Serretti, P. N. Malitas, L. Mandelli, C. Lorenzi, C. Ploia, B. Alevizos, C. Nikolaou, F. Boufidou, G. N. Christodoulou, E. Smeraldi

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

We previously reported an association between the functional polymorphism in the upstream regulatory region of the serotonin transporter gene (SERTPR) and the prophylactic efficacy of lithium in a sample of 201 Italian subjects affected by Mood disorders. The aim of the present study was to replicate analyses on an independent sample. In total, 83 subjects affected by Bipolar disorder were recruited in the Mood Disorders Clinic of the Eginition Hospital of the Athens University, Medical School Department of Psychiatry. All patients were administered with lithium as prophylactic therapy and they were prospectively observed for at least 3 years. Subjects were typed for their SERTPR variant using polymerase chain reaction techniques. SERTPR variants were associated with lithium outcome among those subjects who had few manic episodes before lithium treatment and, as a trend, among subjects who received a high daily dose of lithium (≥ 1200mg/die). In both cases, subjects with the l/l variant showed a higher probability to develop an illness episode within 3 years of prophylactic treatment with lithium. The present study confirmed our previous observation of a better response of SERTPR*l/s carriers, but could not confirm a poor efficacy in subjects with the SERTPR*s/s genotype. Notwithstanding the conflicting results, SERTPR variants are a possible liability factor for lithium long-term efficacy in mood disorders. Further studies on independent and large samples are required to determine the reliability and direction of the possible association between SERTPR variants and lithium outcome.

Original languageEnglish
Pages (from-to)267-273
Number of pages7
JournalPharmacogenomics Journal
Volume4
Issue number4
DOIs
Publication statusPublished - 2004

Fingerprint

Serotonin Plasma Membrane Transport Proteins
Mood Disorders
Lithium
Genes
Nucleic Acid Regulatory Sequences
Medical Schools
Bipolar Disorder
Psychiatry
Therapeutics
Genotype
Observation
Polymerase Chain Reaction

Keywords

  • Bipolar disorder
  • Follow-up studies
  • Lithium
  • Pharmacogenetics

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders. / Serretti, Alessandro; Malitas, P. N.; Mandelli, L.; Lorenzi, C.; Ploia, C.; Alevizos, B.; Nikolaou, C.; Boufidou, F.; Christodoulou, G. N.; Smeraldi, E.

In: Pharmacogenomics Journal, Vol. 4, No. 4, 2004, p. 267-273.

Research output: Contribution to journalArticle

Serretti, A, Malitas, PN, Mandelli, L, Lorenzi, C, Ploia, C, Alevizos, B, Nikolaou, C, Boufidou, F, Christodoulou, GN & Smeraldi, E 2004, 'Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders', Pharmacogenomics Journal, vol. 4, no. 4, pp. 267-273. https://doi.org/10.1038/sj.tpj.6500252
Serretti, Alessandro ; Malitas, P. N. ; Mandelli, L. ; Lorenzi, C. ; Ploia, C. ; Alevizos, B. ; Nikolaou, C. ; Boufidou, F. ; Christodoulou, G. N. ; Smeraldi, E. / Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders. In: Pharmacogenomics Journal. 2004 ; Vol. 4, No. 4. pp. 267-273.
@article{be3078ea57fc4bd5927b17d8b0d70654,
title = "Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders",
abstract = "We previously reported an association between the functional polymorphism in the upstream regulatory region of the serotonin transporter gene (SERTPR) and the prophylactic efficacy of lithium in a sample of 201 Italian subjects affected by Mood disorders. The aim of the present study was to replicate analyses on an independent sample. In total, 83 subjects affected by Bipolar disorder were recruited in the Mood Disorders Clinic of the Eginition Hospital of the Athens University, Medical School Department of Psychiatry. All patients were administered with lithium as prophylactic therapy and they were prospectively observed for at least 3 years. Subjects were typed for their SERTPR variant using polymerase chain reaction techniques. SERTPR variants were associated with lithium outcome among those subjects who had few manic episodes before lithium treatment and, as a trend, among subjects who received a high daily dose of lithium (≥ 1200mg/die). In both cases, subjects with the l/l variant showed a higher probability to develop an illness episode within 3 years of prophylactic treatment with lithium. The present study confirmed our previous observation of a better response of SERTPR*l/s carriers, but could not confirm a poor efficacy in subjects with the SERTPR*s/s genotype. Notwithstanding the conflicting results, SERTPR variants are a possible liability factor for lithium long-term efficacy in mood disorders. Further studies on independent and large samples are required to determine the reliability and direction of the possible association between SERTPR variants and lithium outcome.",
keywords = "Bipolar disorder, Follow-up studies, Lithium, Pharmacogenetics",
author = "Alessandro Serretti and Malitas, {P. N.} and L. Mandelli and C. Lorenzi and C. Ploia and B. Alevizos and C. Nikolaou and F. Boufidou and Christodoulou, {G. N.} and E. Smeraldi",
year = "2004",
doi = "10.1038/sj.tpj.6500252",
language = "English",
volume = "4",
pages = "267--273",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders

AU - Serretti, Alessandro

AU - Malitas, P. N.

AU - Mandelli, L.

AU - Lorenzi, C.

AU - Ploia, C.

AU - Alevizos, B.

AU - Nikolaou, C.

AU - Boufidou, F.

AU - Christodoulou, G. N.

AU - Smeraldi, E.

PY - 2004

Y1 - 2004

N2 - We previously reported an association between the functional polymorphism in the upstream regulatory region of the serotonin transporter gene (SERTPR) and the prophylactic efficacy of lithium in a sample of 201 Italian subjects affected by Mood disorders. The aim of the present study was to replicate analyses on an independent sample. In total, 83 subjects affected by Bipolar disorder were recruited in the Mood Disorders Clinic of the Eginition Hospital of the Athens University, Medical School Department of Psychiatry. All patients were administered with lithium as prophylactic therapy and they were prospectively observed for at least 3 years. Subjects were typed for their SERTPR variant using polymerase chain reaction techniques. SERTPR variants were associated with lithium outcome among those subjects who had few manic episodes before lithium treatment and, as a trend, among subjects who received a high daily dose of lithium (≥ 1200mg/die). In both cases, subjects with the l/l variant showed a higher probability to develop an illness episode within 3 years of prophylactic treatment with lithium. The present study confirmed our previous observation of a better response of SERTPR*l/s carriers, but could not confirm a poor efficacy in subjects with the SERTPR*s/s genotype. Notwithstanding the conflicting results, SERTPR variants are a possible liability factor for lithium long-term efficacy in mood disorders. Further studies on independent and large samples are required to determine the reliability and direction of the possible association between SERTPR variants and lithium outcome.

AB - We previously reported an association between the functional polymorphism in the upstream regulatory region of the serotonin transporter gene (SERTPR) and the prophylactic efficacy of lithium in a sample of 201 Italian subjects affected by Mood disorders. The aim of the present study was to replicate analyses on an independent sample. In total, 83 subjects affected by Bipolar disorder were recruited in the Mood Disorders Clinic of the Eginition Hospital of the Athens University, Medical School Department of Psychiatry. All patients were administered with lithium as prophylactic therapy and they were prospectively observed for at least 3 years. Subjects were typed for their SERTPR variant using polymerase chain reaction techniques. SERTPR variants were associated with lithium outcome among those subjects who had few manic episodes before lithium treatment and, as a trend, among subjects who received a high daily dose of lithium (≥ 1200mg/die). In both cases, subjects with the l/l variant showed a higher probability to develop an illness episode within 3 years of prophylactic treatment with lithium. The present study confirmed our previous observation of a better response of SERTPR*l/s carriers, but could not confirm a poor efficacy in subjects with the SERTPR*s/s genotype. Notwithstanding the conflicting results, SERTPR variants are a possible liability factor for lithium long-term efficacy in mood disorders. Further studies on independent and large samples are required to determine the reliability and direction of the possible association between SERTPR variants and lithium outcome.

KW - Bipolar disorder

KW - Follow-up studies

KW - Lithium

KW - Pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=4344652232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344652232&partnerID=8YFLogxK

U2 - 10.1038/sj.tpj.6500252

DO - 10.1038/sj.tpj.6500252

M3 - Article

VL - 4

SP - 267

EP - 273

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 4

ER -